Sildenafil (Generic) and Finasteride Interaction: What You Need to Know

Are Sildenafil and Finasteride Safe to Take Together?

Yes, sildenafil and finasteride are generally safe to combine. No pharmacokinetic drug-drug interaction has been established between these two agents in primary literature or FDA labeling. The main clinical consideration is that finasteride itself can cause or worsen erectile dysfunction (ED) in a subset of men, which means a patient starting both drugs may need careful ED symptom tracking to separate finasteride-related sexual side effects from inadequate sildenafil dosing.

The FDA-approved label for finasteride 5 mg (Proscar) lists decreased libido, erectile dysfunction, and reduced ejaculate volume as adverse reactions occurring in 1.4 to 3.8% of men in placebo-controlled trials, compared to 0.7 to 1.7% on placebo. [1] The FDA label for sildenafil (Viagra, Revatio) identifies no interaction with 5-alpha reductase inhibitors (5-ARIs) in its drug interaction section. [2]

Why Patients Take Both Drugs

Men with benign prostatic hyperplasia (BPH) or lower urinary tract symptoms (LUTS) frequently receive finasteride 5 mg alongside PDE5 inhibitors. ED co-occurs in up to 72% of men with BPH, per a 2003 cross-sectional analysis published in the European Urology journal. [3] Men taking finasteride 1 mg for androgenic alopecia who also develop ED represent a separate, younger patient population where combination use is also common.

What "No Pharmacokinetic Interaction" Actually Means

Sildenafil is metabolized primarily by CYP3A4 and secondarily by CYP2C9, producing an active N-desmethyl metabolite (UK-103,320) that accounts for roughly 20% of sildenafil's pharmacological effect. [2] Finasteride is also metabolized via CYP3A4 and CYP2C9, but it is neither a meaningful inhibitor nor a meaningful inducer of these enzymes at therapeutic doses. [1] Because neither drug meaningfully alters the other's enzymatic clearance, plasma concentrations of both agents remain predictable when co-administered.

How Finasteride May Affect Erectile Function

Finasteride blocks the conversion of testosterone to dihydrotestosterone (DHT) by inhibiting 5-alpha reductase type II (and type I at higher doses). DHT plays a role in peripheral and central androgen signaling that supports erectile tissue physiology. Reducing DHT may, in some men, impair neurogenic and vascular components of erection.

The MTOPS Trial Data

The landmark Medical Therapy of Prostatic Symptoms (MTOPS) trial (N=3,047) compared finasteride, doxazosin, combination therapy, and placebo in men with BPH over a mean of 4.5 years. Sexual dysfunction was reported more frequently in the finasteride arms. Specifically, decreased libido occurred in 2.5% of finasteride-treated men vs. 1.0% on placebo. [4] Men already experiencing ED before enrollment were more likely to report worsening of erectile symptoms on finasteride.

Post-Finasteride Syndrome: Separating Evidence from Anecdote

A subset of men report persistent sexual dysfunction after stopping finasteride, a presentation sometimes called post-finasteride syndrome (PFS). The biological mechanism remains debated. A 2019 systematic review in the Journal of Sexual Medicine (Irwig, M.S.) found that case series and retrospective studies document persistent symptoms in some men, but prospective controlled data are lacking. [5] Prescribers should document baseline sexual function before initiating finasteride in any patient who might also require PDE5 inhibitor therapy.

Neurosteroid Pathway: A Mechanistic Note

Finasteride reduces levels of neuroactive steroids, including allopregnanolone (3-alpha, 5-alpha-tetrahydroprogesterone), a positive allosteric modulator of GABA-A receptors. A 2011 study in the Journal of Steroid Biochemistry and Molecular Biology (Melcangi et al.) demonstrated altered peripheral nerve steroid profiles in rats treated with finasteride, providing a mechanistic basis for sexual side effects beyond simple DHT reduction. [6] This pathway does not interact with sildenafil's mechanism (cGMP phosphodiesterase-5 inhibition) but matters because it suggests the ED seen with finasteride may not fully respond to PDE5 inhibition in all patients.

Sildenafil's Mechanism and What Can Actually Interfere With It

Sildenafil inhibits PDE5, the enzyme that degrades cyclic guanosine monophosphate (cGMP) in penile smooth muscle. Higher cGMP levels relax smooth muscle, increase arterial inflow, and produce erection in response to sexual stimulation. Nitric oxide (NO) from endothelial cells and parasympathetic nerve terminals drives cGMP synthesis, so sildenafil is permissive rather than initiating.

CYP3A4 Interactions That Do Matter

Finasteride does not inhibit CYP3A4. But other drugs commonly prescribed alongside finasteride do. Strong CYP3A4 inhibitors, including ketoconazole, itraconazole, ritonavir, and erythromycin, can increase sildenafil plasma AUC by as much as 11-fold (ritonavir). [2] If a patient is on finasteride plus a CYP3A4 inhibitor, the sildenafil dose may need to be reduced to 25 mg. The FDA label specifically recommends a starting dose of 25 mg sildenafil when co-administered with a strong CYP3A4 inhibitor. [2]

Alpha-Blocker Caution in BPH Patients

Men with BPH-related LUTS often take alpha-1 blockers (tamsulosin, alfuzosin, doxazosin) in addition to finasteride. Alpha-blockers and sildenafil both lower blood pressure through distinct mechanisms, and their combination can cause symptomatic hypotension. The FDA label for sildenafil warns that concomitant use with alpha-blockers requires caution, and that administration of sildenafil 25 mg within 4 hours of tamsulosin 0.4 mg produced a clinically significant mean maximum decrease in supine systolic blood pressure of 18 mmHg in a dedicated interaction study. [2] This is the most actionable drug interaction concern in men taking finasteride for BPH, not the finasteride itself.

Nitrate Contraindication Remains Absolute

Sildenafil is absolutely contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) and nitric oxide donors regardless of finasteride status. [2] Patients with BPH who also have coronary artery disease requiring nitrate therapy cannot safely use sildenafil.

Evidence on Combination Therapy for BPH-Related ED

The AUA 2021 Clinical Guideline on the Surgical Management of BPH and the companion 2021 pharmacological management update state that PDE5 inhibitors can be used in men with BPH-associated ED and LUTS. Tadalafil 5 mg once daily holds FDA approval for both BPH/LUTS and ED simultaneously. [7] Sildenafil's on-demand dosing model is less studied in this combined indication but remains widely used off-label.

The CombAT Trial Context

The Combination of Avodart and Tamsulosin (CombAT) trial (N=4,844) followed men with BPH on dutasteride (a dual 5-ARI), tamsulosin, or both for 4 years. Sexual adverse events, including ED and ejaculatory dysfunction, were more common in the combination arm (6.3%) than tamsulosin alone (1.8%). [8] While CombAT used dutasteride rather than finasteride, both drugs inhibit 5-alpha reductase type II, and the sexual AE pattern is class-level data. These findings support careful baseline documentation and follow-up when adding a 5-ARI to any regimen.

Tadalafil vs. Sildenafil in LUTS Patients

A 2014 Cochrane review of PDE5 inhibitors for lower urinary tract symptoms (Gacci et al., updated 2022) analyzed 12 randomized trials (N=3,214) and found that PDE5 inhibitor monotherapy significantly improved International Prostate Symptom Score (IPSS) by a mean of 2.8 points vs. Placebo, and International Index of Erectile Function (IIEF) by a mean of 5.5 points. [9] Tadalafil had the most trial data, but sildenafil and vardenafil showed comparable directional effects. Adding an alpha-blocker to a PDE5 inhibitor further improved IPSS, but also increased hypotension risk.

Pharmacokinetic Summary Table

| Parameter | Sildenafil | Finasteride | |---|---|---| | Primary metabolism | CYP3A4 | CYP3A4, CYP2C9 | | Active metabolite | N-desmethyl sildenafil (~20% activity) | None clinically significant | | P-glycoprotein substrate | No | No | | Half-life | 3 to 5 hours | 5 to 6 hours | | Renal dose adjustment | No (mild-moderate) | No | | Hepatic dose adjustment | Yes (Child-Pugh A/B: start 25 mg) | No | | Interaction with each other | None established | None established |

Dosing Guidance When Both Drugs Are Prescribed

Sildenafil standard dosing for ED is 50 mg taken approximately 30 to 60 minutes before sexual activity. The dose may be increased to 100 mg or decreased to 25 mg based on efficacy and tolerability. [2] Finasteride 5 mg is taken once daily for BPH; 1 mg once daily for androgenic alopecia. [1]

Starting Sildenafil in a Finasteride User

No dose modification of sildenafil is required solely because of finasteride. Document baseline IIEF-5 (International Index of Erectile Function, 5-item version) score before prescribing finasteride in any patient at risk for ED. Reassess after 3 to 6 months on finasteride. If ED develops or worsens on finasteride, initiate sildenafil at the standard 50 mg dose before escalating to 100 mg. A blunted response to sildenafil may indicate a neurosteroid or androgen-mediated component of ED that PDE5 inhibition alone may not fully address.

When to Reassess

Patients who fail 4 or more properly taken doses of sildenafil 100 mg with finasteride on board should be re-evaluated for other ED etiologies: vascular disease, hypogonadism (measure total and free testosterone, LH, FSH), psychogenic factors, or worsening BPH-related neuropathy. A 2016 study in BJU International found that men with BPH who failed PDE5 inhibitor therapy had significantly higher rates of undiagnosed testosterone deficiency compared to responders. [10]

Patient Counseling Points

Patients taking both sildenafil and finasteride need practical, direct information.

Sexual Side Effects Are Drug-Specific

If a man reports new-onset ED after starting finasteride, the drug is the probable contributor. Sildenafil added to the regimen addresses the erectile component through PDE5 inhibition, but it does not restore DHT levels or reverse any neurosteroid changes. Some men recover baseline erectile function after stopping finasteride; others do not. This should be disclosed before prescribing finasteride to any sexually active patient.

Timing and Administration

Sildenafil on-demand (50 to 100 mg) does not need to be timed relative to the finasteride daily dose. Finasteride's pharmacodynamic effects are cumulative over weeks; the two drugs work on entirely separate pathways. Sexual stimulation remains required for sildenafil to work.

Food and Alcohol

A high-fat meal delays sildenafil absorption by approximately 1 hour and reduces peak plasma concentration (Cmax) by 29%. [2] Alcohol is not contraindicated but can impair erectile response independently of the drug. Finasteride absorption is unaffected by food. [1]

Monitoring for Scalp-Treatment Patients

Men taking finasteride 1 mg for hair loss are generally younger, often without established cardiovascular disease, and may have different baseline ED risk. The absolute risk of finasteride-related ED in this population was 1.4% vs. 0.7% placebo across clinical trials. [1] Prescribers should nonetheless ask about sexual function at each follow-up visit.

Drug Interactions Checklist for Men on Both Sildenafil and Finasteride

The relevant drug interactions in this combination are driven by sildenafil's pharmacology, not finasteride's. Key interactions to screen for:

• Organic nitrates: Absolute contraindication with sildenafil. [2]
• Strong CYP3A4 inhibitors (ritonavir, ketoconazole, clarithromycin): Reduce sildenafil starting dose to 25 mg. [2]
• Alpha-1 blockers (tamsulosin, doxazosin, terazosin): Allow at least 4 hours between doses; start sildenafil at 25 mg. [2]
• Antihypertensives: Additive blood pressure reduction possible; monitor. [2]
• Amlodipine: Co-administration increased sildenafil AUC by 56% in one pharmacokinetic study; monitor for hypotension. [2]
• CYP3A4 inducers (rifampin, carbamazepine, phenytoin): May reduce sildenafil efficacy by accelerating clearance. [2]

Finasteride has no clinically significant interactions with any of the agents listed above, per its FDA label. [1]